According to a Kauffman study:

Among Emerging Growth Companies firms that made IPOs from 1996 through 2000, only 29 percent were still operating 10 years later. However, acquisition was a far more common outcome than was failure (55 percent vs. 16 percent). Biomedical IPOs had the highest survival and lowest bankruptcy rates among all sectors; the highest failure rates were in manufacturing and retail.